Drugs / WL276 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06691308 | Nov 2024 → May 2027 expected | glioblastoma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WL276 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06691308 ↗ |
| Modality | Cell therapy | “WL276 CAR-T cell therapy” NCT06691308 ↗ |
| Route | Other | “local intracranial administration using the Ommaya device” NCT06691308 ↗ |